20150402 smb inno boot gatt

Presentation Radboud Innovatie BootCamp 2015 Rob Lips

Nijmegen, 2 april 2015 GATT Technologies BV

GATT-Patch

Strategic or Financial investors?

GATT™ synthetic polyoxazoline (POX) platformfor surgical sealants and hemostats

GATT-Tape GATT- Patch

AgendaFrom POX polymer to medical device business opportunity

14 April 2015 GATT Technologies BV 2

About GATT Technologies BV

The GATT-Patch product opportunity

The GATT-Patch industry opportunity

Strategy and financing

Johan Bender MSc Prof Harry v Goor CEO, founder clinical partner serial entrepreneur

About GATT founded with a clinical ambition

14 April 2015 GATT Technologies BV 3

“The GATT technology platform will enable medical device tapes and patches

with specific properties optimized for the targeted clinical

application”

GATT Technologies BV :

founded in 2011 by Johan Bender

The unmet need :

anastomotic leakage: 3-15% with mortality 2-3%

The ambition : the GATT-Tape

About GATTGATT-Tape : technology and successful proofs of concept

14 April, 2015 4

Approved PEG (Polyethyleneglycol ) sealant products

DuraSeal: CoSeal:

Successful Proofs of Concept

GATT-POX advantages over PEG

strong adhesion on wet tissue

water tight < 1-2 minutes

GATT-Tape production

Hot Melt Extrusion

POX poly(2-oxazoline)s has additional benefits:

stronger adhesion better tuneable functionality non-brittle

PEG POX

+ End and side chains+ Versatile synthesis

GATT Technologies BV

GATT-Tapeneeded milestones and financing

14 April, 2015 GATT Technologies BV 5


Strategic Partner

GATT Tape

Technical Proof-of-Concept

X M€

GATT Tape

Pre-Clinical Studies

GATT Tape

Clinical StudiesMilestone CE

GATT Tape

Market intro first Sales

0.X M€ X M€*

X M€ X M€

2015 2016 2018

* intended innovation loans

0.XM€

Financial InvestorsSubsidies/Loans

Financial Investors ?

The large hemostatic and sealant market trend to (semi) synthetic medical devices

14 April 2015 6

productcosts

adhesion strength

Hemostats Sealants

*time to hemostasis

medical device

medicine

2005

Mechanicalhemostats

(1-10 min.)*

PEGsealants

(<2 min.)*


Fibrinpowders(<3 min.)*

Fibringels

(<3 min.)*Fibrin

spray sealants(<5-10 min.)*

Fibrinpatches

(<3 min.)*

POXGATT-Tape

(seal)

POXGATT-Tape

(seal)

The product opportunityclinical need for cost-effective, high-end hemostats

14 April 2015 7

productcosts

adhesion strength

Hemostats Sealants

*time to hemostasis

medical device

medicine

Fibrinpatches

(<3 min.)*

2005

Mechanicalhemostats

(1-10 min.)*

2014 PEGpatches

(<2 min.)*


POXGATT-Patch

(<1 min)*

GATT-Patch> equal/better than Baxter Hemopatch

2017

GATT-Patchcost effective solution in expanding market segment

14 April, 2015 8

The opportunity: Baxter HemoPatch slipstream

BAXTER, recently introduced the Hemopatch

(a sealing hemostat):

PEG-collagen based

hemostatic medical device

competitive pricing

The GATT-Patch will have equal or better

characteristics than the BAXTER Hemopatch

Especially on the faster time to hemostasis (< 1 min.) and at least equal cost effectiveness.

The GATT-Patch will be an attractive and profitable

completion of the product portfolio for most of the major vendors

expensive time to hemostatis 3 min.

The targeted GATT-Patch product


The industry opportunitymarket shift to cost-effective, semi-synthetic medical devices

14 April 2015 9

productcosts

adhesion strength

Hemostats Sealants

*time to hemostasis

medical device

medicine

Fibrinpatches

(<3 min.)*

PEGpatches

(<2 min.)*

POXGATT-Patch

(<1 min)*

1

Mechanicalhemostats

(1-10 min.)*

2


The industry opportunitytargeted companies and confirmed interest

14 April 2015 10

1. Market players with expensive fibrin hemostats:

a competitive high end “sealing” hemostat, is a must for their sales channels

the GATT POX technology will allow for a complete competitive, cost-effective hemostat portfolio

2. Market players with traditional mechanical hemostats:

enables shift of portfolio and expansion of business to attractive high-end

GATT-Patch industry target Matrix:


* <= level as PEG

<< lower than Fibrin

The product opportunity Profitable turnover

14 April, 2015 11

Value chain Turnover

The turnover potential for the GATT-Patch is estimated at 50-150M€ at a targeted 10-20% share in the high end market.

First sales will start at the end of 2017 with a targeted sales turnover of 10-20M€ after 5 years


GATT-Patch BVStrategy: separate legal entity with full business ownership



IP POX technology platform product development supply of activated POX

Strategic Partner

approved carrier + know-how production co-investment (distribution)

GATT Patch BV

business and product owner

exclusive rights on hemostat technology

large OEM partners distributors*

*independent and/or from strategic partner

product supply

GATT-Patch BVdeal construction for partnership GATT-Strategic Partner



Strategic Partner

GATT Patch BV

Technical Proof-of-Concept

GATT-Tech 100%

X M€

GATT Patch BV

Pre-Clinical Studies

GATT-Tech 90%Partner 10%

GATT Patch BV

Milestone CEClinical Studies

GATT-Tech 75%Partner 25%

GATT Patch BV

Market intro operational sales

endorsement studiesGATT-Tech 50%Partner 50%

0.X M€ X M€*

X M€ X M€

2015-Q2 2016-Q2 2017

* intended innovation loans

0.XM€

GATT-Patch

Strategic or Financial investors?

GATT-Tape

Financial Investor

GATT- Patch

Strategic Investor

GATT Technologies BV Rob Lips [email protected]

mailto:[email protected]

20150402 smb inno boot gatt

Documents

Transcript of 20150402 smb inno boot gatt